A randomized phase 2 study comparing different dose-approaches of induction treatment (first cycle) of regorafenib in metastatic colorectal cancer (mCRC) patients
收藏NIAID Data Ecosystem2026-03-09 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2535505
下载链接
链接失效反馈官方服务：
资源简介：
Primary objectives: To evaluate the safety and tolerability of different dose-escalation approaches of regorafenib in mCRC patients.
Primary endpoints: Percentage of patients with G3/G4 treatment-related AEs in each arm according to CTCAE v4.03 criteria.
创建时间：
2016-06-15
